The BridgePoint Medical System (consisting of the CrossBoss™ Catheter, Stingray™ Catheter, and Stingray™ Guidewire) is intended to facilitate the intraluminal placement of conventional guidewires beyond stenotic coronary lesions (including chronic total occlusions) prior to PTCA or stent intervention.

Clinical Program

• Pre-Clinical
• First in Man
• FAST-CTOs Study
  • Case Study - RCA 1
  • Case Study - LAD
  • Case Study - RCA 2

Our Products

• CrossBoss™ CTO Catheter
• Stingray™ CTO Re-Entry System
• Technology Animation

FAST-CTOs Study

Enrollment in FAST-CTOs - Facilitated Antegrade Steering Technique in Chronic Total Occlusions - initiated in Europe and planned for the United States

Up to 300 patients (150 US; 150 EU) presenting with a CTO refractory to conventional guidewire use - defined by one of the following:

• A minimum of 10 minutes of fluoroscopy time with the cardiologist’s choice of guidewire(s) unable to cross
• Previous crossing attempt
• Or if best effort attempts result in the conventional guidewire antegrade advancement into the subintimal plane

Technical Success Defined As:
The ability of the CrossBoss™ CTO Catheter, Stingray™ CTO Orienting Balloon Catheter and/or Stingray™ Re-Entry Guidewire to successfully facilitate placement of a guidewire beyond a CTO in the vessel true lumen in cases that were otherwise refractory to treatment with a conventional guidewire.

Safety Endpoint: 30-Day MACE Rates

For more info on Clinical Study Design

Procedure Sequence